Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046031 in Advanced Melanoma and Solid Tumors
NCT06799533Phase 1Terminated
- Sponsor
- Pfizer
- Start
- May 2025
- Primary completion
- Feb 2026
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of PF-08046031 in melanoma and solid tumor, sponsored by Pfizer. Primary endpoints: Adverse Events at 6 months, Laboratory Abnormalities at 6 months and 1 more. Started May 2025; status: terminated.
02
Drugs
PF-08046031
03
Conditions
melanomasolid tumor
Beyond the preview
Go deeper on NCT06799533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799533.